Category: by country

Authors pull Science paper on molecular wires for “inappropriate data handling”

pic.mag.current-issueThis week’s issue of Science includes a retraction of a highly cited paper about manipulating the current in a string of molecules with a magnet, after an investigation by the co-authors revealed “inappropriate data handling” by the first author.

According to the note, the co-authors’ suspicions arose when they tried to follow-up on the data. Following a “thorough investigation,” they concluded that first author Rabindra N. Mahato had handled the data in such a way that they could no longer trust the conclusions. In the end, Mahato agreed to the retraction.

Here’s more from the note: Continue reading Authors pull Science paper on molecular wires for “inappropriate data handling”

Where I think Retraction Watch went wrong: A guest post from Paolo Macchiarini

Paolo Macchiarini
Paolo Macchiarini

We are pleased to present a guest post by Paolo Macchiarini, a surgeon best known for pioneering the creation of tracheas from cadavers and patients’ own stem cells. Macchiarini has faced some harsh criticisms over the years, including accusations of downplaying the risks of the procedure and not obtaining proper consent. We have covered the investigation, including the recent verdict by Karolinska Institutet that he acted “without due care,” but was not guilty of misconduct. He has taken issue with some aspects of our coverage, and has written a guest post to present his side of the story. We welcome such debate, and have included a short response at the end of his post.

I admire the underlying aims of Retraction Watch.  That might come as a surprise to some readers of the site, given that it has a whole page devoted to me in its archives.  However, I believe passionately that scientific misconduct is a serious crime.  It not only undermines the very purpose of science, but has victims as well, especially in clinical specialisms.  It is vital that misconduct is detected, that fraudulent work is retracted and those retractions made public.  That is why I support Retraction Watch’s aims.  But I am not writing in wholehearted support of the site. Continue reading Where I think Retraction Watch went wrong: A guest post from Paolo Macchiarini

So you want to be a whistleblower? Part III

John Thomas
John Thomas

This is the third and final article in a series by John R. Thomas, Jr., a lawyer at Gentry Locke [Editor’s note, 3/26/19: He has since moved to Haley, Hafemann, Magee and Thomas] who represents whistleblowers in a variety of False Claims Act cases.  His first article discussed the background of the False Claims Act (“FCA”) and how it might apply to scientific misconduct, and his second article provided advice on how to know if you have a viable FCA case. In this installment, he writes about the procedure for bringing an FCA case and how the damages and whistleblower’s share are calculated.

Suppose you are a potential whistleblower. You believe that your PI is manipulating data in publications. You suspect that a fellow lab technician is tampering with experiments. You are a PI who knows that your colleague is “double dipping” on Federal grants. What should you do? Continue reading So you want to be a whistleblower? Part III

Authors “did not have permission” to use pesticide data

10661An environmental journal is retracting an article about the risks of pesticides to groundwater after determining it contained data that “the authors did not have permission (implicit or explicit) to publish.”

According to the retraction note in Environmental Monitoring and Assessment, the paper said the data came from a non-author’s PhD thesis, but it’s not there. Those mysterious data were used to validate a model for pesticide exposures, described in an excerpt from the abstract:  Continue reading Authors “did not have permission” to use pesticide data

Image issues force retraction of liver transplant papers

ajtranspA group of researchers in Hong Kong and China have lost a pair of papers on liver transplantation after concerns were raised about the “origin of images” in the two studies.

The articles appeared in the American Journal of Transplantation in January and February of 2006, and came from the lab of S. T. Fan, of the University of Hong Kong. When the authors were asked about the images, they “were unable to satisfactorily mitigate the concerns.”

According to this bio from the journal Hepatobiliary Surgery and Nutrition, Fan: Continue reading Image issues force retraction of liver transplant papers

Urologist makes what he calls “clarifications” to multiple articles

Screen Shot 2015-09-30 at 10.22.32 AMWe have discovered several errata for a New York City urologist, including in one paper that previously inspired one of our favorite headlines.

The latest development is pretty straightforward: Ashutosh K. Tewari has issued errata to multiple papers in two journals that note changes to some data points. But the backstory has some twists and turns, so you may need to read this one carefully.

We’ll start with the paper that might be familiar to eagle-eyed readers, on incontinence after surgery: “Effect of a Risk- Grade of Nerve-sparing Technique on Early Return of Continence After Robot-assisted Laparoscopic Radical Prostatectomy.” It was published in European Urology in 2012, and has been cited 21 times, according Thomson Scientific’s Web of Knowledge. Here’s the correction note (paywalled  — tsk, tsk):

Continue reading Urologist makes what he calls “clarifications” to multiple articles

Cochrane withdraws review on zinc for colds for data concerns

Cochrane_LogoThe Cochrane Library has withdrawn a 2013 systematic review on zinc’s ability to fight the common cold.

Cochrane often marks reviews “withdrawn” once new evidence emerges that renders them out of date — but in this case, the review was flagged while the editors investigate issues “regarding the calculation and analysis of data.”

Here’s the notice.

Continue reading Cochrane withdraws review on zinc for colds for data concerns

Journal bans authors of duplicated asthma paper

22A common ailment known as duplication has taken down a paper about a common fungus and asthma.

Aspergillus spores are often ubiquitous yet harmless, but can irritate people whose lungs aren’t in top working order. Duplication, on the other hand, is more universally deadly. The editors of The Pan African Medical Journal told us that, in addition to the retraction, there were personal consequences for the authors:  Continue reading Journal bans authors of duplicated asthma paper

Mystery: PLOS One seeks investigation after publishing two papers with “substantial overlap”

Screen Shot 2015-10-01 at 4.27.21 PMPLOS One has retracted one of two cancer papers with “substantial overlap” that were reviewed simultaneously by different editors.

This one’s a bit of a mystery — neither of the papers share an author, and no authors share institutions. Once the editors discovered the overlap, they contacted the authors. One group of authors provided the requested documentation for the experiments. The other did not — so the editors retracted that article, even though it was published months before the other one.

In the meantime, the editors have asked the authors’ institutions investigate how the articles — which contain entire identical sentences, and some extremely similar figures — were put together. According to a statement from the editors:

Continue reading Mystery: PLOS One seeks investigation after publishing two papers with “substantial overlap”

There’s “no evidence” research was conducted at all in retracted cancer paper

cov200h (1)To one reader of a paper on a nerve cancer, the researchers, based at a hospital in China, seemed to have found a very large number of cases of a rare cancer to study. That observation triggered an investigation into the paper that led to its retraction — and the concern that the authors in the paper never did the research at all.

The authors say they recruited 156 patients who had a particular kind of cancer that affects the tissue around nerves, known as malignant peripheral nerve sheath tumors. For context on how rare that is: Other researchers found a mere 1,182 new cases over a nearly four-decade period in the U.S. The study, according to the methods section of the paper, was supposedly done with patients who had a specific type of the disease, and who were

consecutively recruited from Wuhan Union Hospital, Huazhong University of Science and Technology in Wuhan (Hubei, China) between July 2000 and November 2012

According to the retraction note for “Common genetic variants in the microRNA biogenesis pathway are associated with malignant peripheral nerve sheath tumor risk in a Chinese population,” the hospital where the work was done never treated all of those patients:

Continue reading There’s “no evidence” research was conducted at all in retracted cancer paper